Previous 10 | Next 10 |
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare disease...
2023-11-28 14:14:56 ET More on Arcturus, CSL, etc. CSL Limited: Positive Capital Return And Earnings Growth Expectations From Financial Metrics To mRNA Milestones: Arcturus Therapeutics' Evolving Journey Arcturus: COVID Vaccine Approval Shots In Japan And Europe Key ...
Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults PR Newswire Exclusive Partner in Japan , Meiji Seika Pharma advances regulatory approval ...
Exclusive Partner in Japan, Meiji Seika Pharma advances regulatory approval This historic approval of the world's first Self-Amplifying messenger RNA (sa-mRNA) COVID-19 Vaccine underscores CSL's promise to develop and deliver innovations when there is a public health need First ...
2023-11-27 13:13:29 ET U.S. President Joe Biden plans to invoke the Defense Production Act of 1950 to build up domestic production of essential drugs, as one of the many actions announced during the first meeting of his new supply chain resilience council. The Cold War-era federal l...
First cystic fibrosis patient in Phase 1b study successfully completed two administrations of ARCT-032 On track to share interim Phase 1b data in H1 2024 Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stag...
2023-11-22 02:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-11-17 03:01:07 ET Summary Arcturus Therapeutics is a biotech firm focused on mRNA vaccine development and delivery technologies. The company's core investment thesis is centered around its cutting-edge research and its ability to derive revenue from its collaborations. Th...
2023-11-17 01:06:56 ET Summary The article provides an investment overview of Arcutus, offering insights and analysis, and ways of thinking about the investment opportunity. Arcutus is an mRNA specialist developer with no approved products to date - the company missed out on the C...
2023-11-15 05:06:44 ET Related stories: Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2023 Earnings Call Transcript Cellectis SA (CLLS) Q3 2023 Earnings Call Transcript JD.com: Catch The Falling Knife Again? Better Think Twice (Rating Downgrade) Tiger Global ...
News, Short Squeeze, Breakout and More Instantly...
Arcturus Therapeutics Ltd. Company Name:
ARCT Stock Symbol:
NASDAQ Market:
Arcturus Therapeutics Ltd. Website:
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, toda...
2024-07-02 10:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for ARCT on July 2, 2024 08:19AM ET. The previous analyst recommendation was Overweight. ARCT was trading at $23.66 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
ARCT-810 Phase 2 study completed enrollment at 0.3 mg/kg dose level in Europe with data expected later this year ARCT-810 to expand Phase 2 clinical program in the U.S. to enroll patients with more severe disease ARCT-032 IND for Phase 2 multiple ascending dose study to be submitt...